ACB
Aurora Cannabis·NASDAQ
--
--(--)
--
--(--)
ACB fundamentals
Aurora Cannabis (ACB) released its earnings on Feb 4, 2026: revenue was 68.58M (YoY +11.89%), beat estimates; EPS was 0.0218 (YoY -94.50%), missed estimates.
Revenue / YoY
68.58M
+11.89%
EPS / YoY
0.0218
-94.50%
Report date
Feb 4, 2026
ACB Earnings Call Summary for Q3,2026
- Revenue Growth: 7% YoY increase to CAD 94.2 million, with 12% growth in global medical cannabis (CAD 76.2 million). Over half of revenue generated outside Canada.
- Strategic Shift: Exiting Canadian consumer cannabis to focus on high-margin global medical markets, generating 81% of revenue from medical cannabis.
- Financial Strength: Adjusted EBITDA of CAD 18.5 million, free cash flow of CAD 15.5 million, and CAD 154 million in cash with no debt.
- Market Leadership: Leading positions in Germany, Poland, and Australia, with Germany's imports doubling in 2025 and Poland's regulatory adaptability.
- Future Growth: Global medical cannabis revenue expected to rise 10%-15% to CAD 269-281 million, supported by ATM program for strategic M&A.
EPS
Actual | -9.6252 | -122.3201 | -6.7378 | -13.6578 | -6.7629 | -5.3299 | -1.32 | -1.4452 | -1.8443 | -0.6035 | 0 | -0.3773 | -0.2953 | 0.0585 | -0.1626 | 0.3961 | -0.2432 | -0.191 | -0.6534 | 0.0218 | ||||||||||
Forecast | -5.8219 | -4.8243 | -3.128 | -2.4306 | -1.9509 | -2.1774 | -0.99 | -0.6232 | -1.918 | -0.3923 | -0.4785 | -0.1014 | -0.1329 | -0.1266 | -0.0797 | 0.0034 | 0.0879 | 0.1195 | 0.0112 | 0.0972 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -65.33% | -2435.50% | -115.40% | -461.91% | -246.66% | -144.78% | -33.33% | -131.90% | +3.84% | -53.84% | +100.00% | -272.09% | -122.20% | +146.21% | -104.02% | +11550.00% | -376.68% | -259.83% | -5933.93% | -77.57% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 53.06M | 52.95M | 50.77M | 53.12M | 43.89M | 44.26M | 38.25M | 44.58M | 47.23M | 56.66M | 46.67M | 48.60M | 49.76M | 60.97M | 59.95M | 61.29M | 62.91M | 72.00M | 64.88M | 68.58M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 47.58M | 53.72M | 47.59M | 54.50M | 54.68M | 45.53M | 40.81M | 40.45M | 47.95M | 56.86M | 46.44M | 47.82M | 51.34M | 56.67M | 51.56M | 55.50M | 61.72M | 70.76M | 62.05M | 67.26M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +11.50% | -1.43% | +6.68% | -2.54% | -19.74% | -2.77% | -6.27% | +10.22% | -1.50% | -0.36% | +0.50% | +1.63% | -3.07% | +7.57% | +16.29% | +10.43% | +1.93% | +1.75% | +4.57% | +1.95% |
Earnings Call
You can ask Aime
Did Aurora Cannabis beat or miss consensus estimates last quarter?What is the market's earnings forecast for Aurora Cannabis next quarter?What does Aurora Cannabis do and what are its main business segments?What were the key takeaways from Aurora Cannabis’s earnings call?What is the revenue and EPS growth rate for Aurora Cannabis year over year?What is Aurora Cannabis's gross profit margin?What guidance did Aurora Cannabis's management provide for the next earnings period?What factors drove the changes in Aurora Cannabis's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
